3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Endocrine
1
Conditions
Carcinoma, Non-Small-Cell Lung
50
Lung Neoplasms
13
Neoplasms
8
Melanoma
6
Neoplasm Metastasis
5
Head and Neck Neoplasms
5
Squamous Cell Carcinoma of Head and Neck
4
Breast Neoplasms
4
Urinary Bladder Neoplasms
3
Triple Negative Breast Neoplasms
3
Stomach Neoplasms
3
Ovarian Neoplasms
3
Colorectal Neoplasms
3
Carcinoma, Merkel Cell
3
Carcinoma, Hepatocellular
3
Uterine Cervical Neoplasms
2
Prostatic Neoplasms
2
Pancreatic Neoplasms
2
Mesothelioma, Malignant
2
Gastrointestinal Neoplasms
2
Colonic Neoplasms
2
Carcinoma, Squamous Cell
2
Carcinoma, Renal Cell
2
Carcinoma, Large Cell
2
Carcinoma, Basal Cell
2
Brain Neoplasms
2
Advanced Non-Small Cell Lung Cancer
2
Adenocarcinoma
2
Vaccinia
1
Uterine Neoplasms
1
Interventions
zenocutuzumab
1
seribantumab
1
pembrolizumab
1
osimertinib
1
enzalutamide
1
cemiplimab
1
Vascular Endothelial Growth Factor A
1
Paroxetine
1
Paclitaxel
1
Itraconazole
1
Erlotinib Hydrochloride
1
Docetaxel
1
Carboplatin
1
Antibodies, Bispecific
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Lethal Congenital Contracture Syndrome 2
×
cemiplimab
×
Thoracic
×
Clear all
NCT05142189
2026-04-14
LuCa-MERIT-1
BioNTech SE
Phase 1
Recruiting
320 enrolled